Optiscan Imaging Limited · ASX:OIL
Optiscan Imaging — Investor Presentation (March 2019)
20 slides from Optiscan Imaging's investor presentation, Mar 14, 2019
Slide 1: OptiScan March 2019 Presentation (Amended)
For personal use only ASX Announcement 14 March 2019 OptiScan March 2019 Presentation (Amended) Optiscan Imaging Limited (ASX: OIL) provides the attached amended presentation to the previous version lodged on 14 March 2019. It is noted that the only amendment to the previous version is to slide 16 o
Slide 2: Letter to shareholders
For personal use only ASX Announcement 14 March 2019 OptiScan March 2019 Presentation Dear Shareholders, Optiscan Imaging Limited (ASX: OIL) is pleased to provide this presentation on the development of additional human applications for the use of Optiscan’s confocal laser endomicroscope technology.
Slide 3: Optiscan Imaging Ltd – Unlocking the Potential in Human Applications
Optiscan Imaging Ltd For personal use only (ASX:OIL) Diagnostic and Intraoperative Clinical Devices “Unlocking the Potential in Human Applications”
Slide 4: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Optiscan Imaging Limited (OIL). This presentation contains summary information about OIL which is current as at 14 March 2019. Neither the OIL, nor any of its officers, employees, officers, agents, consultants or advisers are un
Slide 5: Disclaimer
Disclaimer For personal use only Past performance The operating and historical financial information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of OIL's views on its future performance or condition. Actual results co
Slide 6: Optiscan Imaging Ltd – New Human Clinical Application Developments
Optiscan Imaging Ltd For personal use only Developer and Manufacturer of Clinical and Translational EndoMicroscopes New Human Clinical Application Developments ▪ Product development and modifications to the FIVE2 (ViewnVivo) being undertaken to enable oral, cervical, breast and other human clinical
Slide 7: Clinical and Pre-Clinical Applications
Clinical and Pre-Clinical Applications For personal use only CLINICAL PRE-CLINICAL APPLICATION STATUS APPLICATIONS APPLICATION BREAST CERVICAL ORAL OESAPHAGEAL NEURO PRE-CLINICAL Device Optiscan Rigid Optiscan Rigid Optiscan Rigid Flexible FIVE2 (ViewnVivo) Endomicroscope Endomicroscope Endomicrosco
Slide 8: ASX Announcements
ASX Announcements For personal use only Memorial Sloan Kettering Cancer ASX Announcement Centre (MSKCC) Announcement 26 February 2019 26 February 2019 OptiScan technology used in research at major cancer center Optiscan is pleased to announce that Memorial Sloan Kettering Cancer Center (MSK) in New
Slide 9: PARPi-FL – Optical and Diagnostic Imaging Agent
PARPi-FL – Optical and Diagnostic Imaging Agent For personal use only PARPi-FL ▪ A molecular based imaging agent ▪ Possesses unique pharmacokinetics properties for topical as well as intravenous injection ▪ Targeting PARP1, an enzyme that is highly overexpressed in several human cancers such as oral
Slide 10: What is PARP1 and PARP1 Inhibitors?
What is PARP1 and PARP1 Inhibitors? For personal use only Poly(ADP-ribose) polymerase PARP1, is an enzyme in the cell nucleus which is activated by DNA damage acting as a ‘molecular nick sensor’ to signal DNA single-strand breaks (SSBs) and assist in their repair. It is significantly over expressed
Slide 11: Breast, Cervical, Oral and Oesophageal Cancer
Breast, Cervical, Oral and Oesophageal Cancer For personal use only Estimated incidence of cancer types below with far higher number of potential diagnostic assessments * American Cancer Society Estimated 2019 Statistics. ** Cancer Statistics in China, 2015, published in CA: A Cancer Journal for Cli
Slide 12: Opportunities for Improved Patient Outcomes: Breast Cancer
Opportunities for Improved Patient Outcomes with Optiscan Confocal Laser Endomicroscopy (CLE) For personal use only BREAST CANCER ▪ 13% and 15% of all cancers in Australia and the United States respectively. ▪ “Best estimates suggest that 60–80% of women with early-stage breast cancer in Australia u
Slide 13: Assessment of Breast Cancer Surgical Margin
Assessment of Breast Cancer Surgical Margin For personal use only ▪ 271,270 estimated new cases of invasive breast cancer diagnosed in the United States in 2019 and 18,235 new cases diagnosed in Australia in 2018. ▪ Nearing completion of Stage 1 of breast cancer surgical margin assessment trial. Ima
Slide 14: Opportunities for Improved Patient Outcomes: Oral Cancer
Opportunities for Improved Patient Outcomes with Optiscan Confocal Laser Endomicroscopy (CLE) For personal use only ORAL CANCER ▪ Comprise 85% of head and neck cancers (excluding brain cancers). Worldwide, there are over 450,000 new cases each year. 1 ▪ 53,000 Americans will be diagnosed with oral o
Slide 15: Opportunities for Improved Patient Outcomes: Cervical Cancer
Opportunities for Improved Patient Outcomes with Optiscan Confocal Laser Endomicroscopy (CLE) For personal use only CERVICAL CANCER ▪ Cervical cancer is the fourth most common cancer among women globally. In Australia, there were 930 new cases in 2018 and 258 deaths and in the USA for 2019 it is est
Slide 16: Cervix – CLE and Histopathology Correlation
Cervix – CLE and Histopathology Correlation For personal use only “The majority of the decline in invasive cervical cancer rates in developed countries is due to a reduction in squamous cell carcinoma. In contrast, the incidence of adenocarcinomas has not declined, largely attributed to difficulties
Slide 17: Sterilizable Probe Sheath
Sterilizable Probe Sheath For personal use only Design of Optiscan’s sterilizable sheath completed. Third party validation testing to be undertaken in the near term. 15
Slide 18: Carl Zeiss Meditec (CZM) Collaboration
Carl Zeiss Meditec (CZM) Collaboration For personal use only ▪ FDA510(k) and CE Mark for CZM Convivo ▪ CZM advises commercialisation progressing in neurosurgery Belykh E, Cavallo C, Gandhi S, Zhao X, Veljanoski D, Izady Yazdanabadi M, et al. Utilization of intraoperative confocal laser endomicroscop
Slide 19: Translational and Pre-Clinical Research
Translational and Pre-Clinical Research For personal use only ▪ Increased profile in Australian translational and pre-clinical research markets. ▪ Multi-faceted re-branding of FIVE2 (ViewnVivo) including new website in late 2018. ▪ Conducted workshop at Light Microscopy Association conference in Bri
Slide 20: Summary and Future Outlook
Summary and Future Outlook For personal use only ▪ A strategic transformation of Optiscan has taken place over the last 10 months. ▪ Optiscan CLE is being enabled for intraoperative and diagnostic use in the operating theatre, medical and dental clinic and pathology laboratory. ▪ Human applications
Optiscan Imaging — Investor Presentation (March 2019) on 6ix